טוען...
Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC)
We conducted a study of combined treatment with docetaxel, bevacizumab, and everolimus in patients with chemotherapy-naive metastatic castrate-resistant prostate cancer. Although we establish a safe dose for coadministration of these 3 agents and our early results suggested encouraging levels of ant...
שמור ב:
| הוצא לאור ב: | Clin Genitourin Cancer |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7444943/ https://ncbi.nlm.nih.gov/pubmed/28826933 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.07.003 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|